Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 29 tags : Als save search
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
Published: 2021-12-29 (Crawled : 21:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -0.08%
H: 0.38%
C: -1.21%
als
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
Published: 2021-12-29 (Crawled : 17:00) - biospace.com/
MYMD | $2.54 0.8% 0.79% 18K
|
Manufacturing
|
| O: 2.19%
H: 3.39%
C: -1.96%
ORMP A | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: 1.69%
H: 5.38%
C: -0.76%
covid-19 als covid vaccine
Can front desk perceptions at hospitals actually make a patient’s experience better?
Published: 2021-12-29 (Crawled : 15:00) - nrchealth.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 0.13%
H: 1.13%
C: -0.88%
als
Global Cement Market Report 2021-2025, Featuring Profiles of Key Players Anhui Conch, Holcim, HeidelbergCement AG, Cemex, Vulcan Materials and Eagle Materials
Published: 2021-12-29 (Crawled : 15:00) - prnewswire.com
HDELY | $19.976 -8.79% 66K
|
Manufacturing
|
| O: -0.22%
H: 0.74%
C: 0.74%
VMC | $252.06 -1.18% 0.0% 610K
|
Non-Energy Minerals
|
| O: -0.52%
H: 1.08%
C: 0.58%
EXP 4 | $238.19 -1.73% -1.98% 520K
|
Non-Energy Minerals
|
| O: 0.32%
H: 1.37%
C: 0.71%
als
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
Published: 2021-12-29 (Crawled : 14:00) - biospace.com/
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: -2.86%
H: 5.69%
C: -3.43%
als ongoing trial phase 1 phase 2 milestone phase 3
Universe Pharmaceuticals INC Announces Strategic Alliance with Jinggangshan University for Study on the Chemical Constituents of Certain Traditional Chinese Medicine
Published: 2021-12-29 (Crawled : 14:00) - biospace.com/
UPC | $2.19 8.76% 95K
|
Manufacturing
|
| O: -3.59%
H: 4.35%
C: -0.62%
chinese als
Amylyx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application (NDA) for AMX0035 for the Treatment of ALS
Published: 2021-12-29 (Crawled : 13:30) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M
|
| Email alert
Add to watchlist
amx0035 new drug treatment fda als application drug fda acceptance
Finward Bancorp and Royal Financial, Inc. Announce Receipt of Regulatory Approvals and Election Deadline
Published: 2021-12-29 (Crawled : 13:30) - globenewswire.com
FNWD 4 | $24.64 -0.73% -0.73% 3.7K
|
Finance and Insurance
|
| O: -1.92%
H: 0.0%
C: 0.0%
als approval deadline
NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
Published: 2021-12-29 (Crawled : 12:30) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 10.22%
H: 4.84%
C: 0.2%
covid-19 zyesami treatment aviptadil als risk covid media therapy breakthrough therapy designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.